Form 8-K - Current report:
SEC Accession No. 0001437749-22-011504
Filing Date
2022-05-09
Accepted
2022-05-09 16:00:50
Documents
14
Period of Report
2022-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K atos20220427_8k.htm   iXBRL 8-K 34804
2 EXHIBIT 99.1 EARNINGS RELEASE 3.31.2022 ex_372135.htm EX-99.1 62345
  Complete submission text file 0001437749-22-011504.txt   236318

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atos-20220509.xsd EX-101.SCH 3600
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atos-20220509_def.xml EX-101.DEF 11531
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE atos-20220509_lab.xml EX-101.LAB 15413
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atos-20220509_pre.xml EX-101.PRE 11687
8 EXTRACTED XBRL INSTANCE DOCUMENT atos20220427_8k_htm.xml XML 2556
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 22904770
SIC: 2834 Pharmaceutical Preparations